{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:30:46Z","timestamp":1792801846533,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Med Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primaquine is a gametocytocidal drug known to significantly reduce malaria transmission. However, primaquine induces a dose-dependent acute hemolytic anemia (AHA) in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency that has led to a\u00a0limited use of the drug especially in Africa where the condition is common. The World Health Organization (WHO) now recommends a single low dose (SLD) of primaquine (0.25\u00a0mg\/kg) as <jats:italic>P. falciparum<\/jats:italic> gametocytocidal without the need for prior screening of G6PD status. Adoption and implementation of SLD primaquine in Africa may probably reduce malaria transmission, a pre-requisite for malaria elimination. This review therefore, focused on the safety of primaquine for control of malaria in Africa. The literature search was performed using online database Google Scholar, PubMed, HINARI, and Science Direct. Search terms used were \u201cmalaria\u201d, \u201cprimaquine\u201d, \u201csafety\u201d, \u201cG6PD deficiency\u201d, \u201clarge scale\u201d or \u201cmass administration\u201d. Clinical trials in many African countries have shown SLD primaquine to be safe especially in a milder African G6PD A- variant. Likewise, large-scale primaquine administrations outside Africa involving hundreds of thousands to tenths of millions of participants and with severe variants of G6PD deficiency have also shown primaquine to be safe and well-tolerated. Fourteen deaths associated with primaquine have been reported globally over the past 6 decades, but none occurred following the administration of SLD primaquine. Available evidence shows that the WHO-recommended SLD primaquine dose added to effective schizonticides is safe and well-tolerated even in individuals with G6PD deficiency, and therefore, it can be safely used in the African population with the mildest G6PD A- variant.<\/jats:p>","DOI":"10.1186\/s41182-022-00408-5","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T08:02:44Z","timestamp":1645776164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Is it time for Africa to adopt primaquine in the era of malaria control and elimination?"],"prefix":"10.1186","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-4304","authenticated-orcid":false,"given":"Richard O.","family":"Mwaiswelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamis","family":"Kabuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliningaya J.","family":"Kweka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"408_CR1","unstructured":"WHO. World malaria report 2019. World Health Organization, Geneva, Switzerland. 2019. Accessed 13 Jan 2021."},{"key":"408_CR2","unstructured":"WHO. World malaria report 2021. World Health Organization. Geneva, Switzerland. 2021. Accessed 14 Feb 2022"},{"key":"408_CR3","unstructured":"WHO. World Malaria Report 2015. World Health Organization, Geneva, Switzerland. 2015. Accessed 14 Jan 2021"},{"key":"408_CR4","unstructured":"WHO. Weekly epidemiological record. World Health Organization, Geneva, Switzerland. 2017. Accessed 17 Jan 2021."},{"key":"408_CR5","unstructured":"RBM. Economic costs of malaria. 2010. Available at: https:\/\/www.malariaconsortium.org\/userfiles\/file\/Malaria%20resources\/RBM%20Economic%20costs%20of%20malaria.pdf. Accessed on 20 Jan 2021."},{"issue":"6872","key":"408_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/415680a","volume":"415","author":"J Sachs","year":"2002","unstructured":"Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680\u20135.","journal-title":"Nature"},{"key":"408_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4269\/ajtmh.2001.64.85","volume":"64","author":"JL Gallup","year":"2001","unstructured":"Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg. 2001;64:85\u201396.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"408_CR8","doi-asserted-by":"publisher","first-page":"2012048","DOI":"10.4084\/mjhid.2012.048","volume":"4","author":"F Ricci","year":"2012","unstructured":"Ricci F. Social implications of malaria and their relationships with poverty. Mediterr J Hematol Infect Dis. 2012;4(1):2012048.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"408_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1475-2875-13-51","volume":"13","author":"A Kondrashin","year":"2014","unstructured":"Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51.","journal-title":"Malar J"},{"key":"408_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low - dose of primaquine in addition to standard artemether\u2014lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.","journal-title":"Malar J"},{"issue":"4","key":"408_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/cix355","volume":"65","author":"RC Tine","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to Reduce gametocyte carriage: a randomized controlled trial. Clin Infect Dis. 2017;65(4):535\u201343.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"408_CR12","doi-asserted-by":"publisher","first-page":"e0190272","DOI":"10.1371\/journal.pone.0190272","volume":"13","author":"GJH Bastiaens","year":"2018","unstructured":"Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gon\u00e7alves BP, et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials. PLoS ONE. 2018;13(1):e0190272.","journal-title":"PLoS ONE"},{"key":"408_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1473-3099(15)00479-X","volume":"16","author":"A Dicko","year":"2016","unstructured":"Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis. 2016;16:6.","journal-title":"Lancet Infect Dis"},{"key":"408_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"408_CR15","unstructured":"Systematic evidence review from the obesity expert panel 2013. Managing overweight and obesity in adults. 2013. Available from: https:\/\/www.nhlbi.nih.gov\/sites\/default\/files\/media\/docs\/obesity-evidence-review.pdf. Accessed on 20 Sept 2021."},{"issue":"6","key":"408_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1473-3099(04)01043-6","volume":"4","author":"SI Hay","year":"2004","unstructured":"Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004;4(6):327\u201336.","journal-title":"Lancet Infect Dis"},{"key":"408_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cmi.2016.04.023","volume":"22","author":"ET Piperaki","year":"2016","unstructured":"Piperaki ET, Daikos GL. Malaria in Europe: emerging threat or minor nuisance\u202f? Clin Microbiol Infect. 2016;22:487\u201393.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"408_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/cmdc.200600240","volume":"2","author":"M Schlitzer","year":"2007","unstructured":"Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem. 2007;2(7):944\u201386.","journal-title":"ChemMedChem"},{"issue":"3","key":"408_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","volume":"44","author":"N Vale","year":"2009","unstructured":"Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem. 2009;44(3):937\u201353.","journal-title":"Eur J Med Chem"},{"key":"408_CR20","unstructured":"WHO. Global Malaria Control and Elimination. World Health Organization, Geneva, Switzerland. 2008. Accessed on 21 Sept 2021."},{"key":"408_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7705\/biomedica.v22i4.1171","volume":"22","author":"CF Curtis","year":"2002","unstructured":"Curtis CF. Should the use of DDT be revived for malaria vector control\u202f? Biomedica. 2002;22:455\u201361.","journal-title":"Biomedica"},{"issue":"1","key":"408_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/archdischild-2013-305441","volume":"100","author":"S Owens","year":"2015","unstructured":"Owens S. Malaria and the millennium development goals. Arch Dis Child. 2015;100(1):53\u20136.","journal-title":"Arch Dis Child"},{"key":"408_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/1475-2875-11-360","volume":"11","author":"AC Eziefula","year":"2012","unstructured":"Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, von Seidlein L, et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J. 2012;11:360.","journal-title":"Malar J"},{"issue":"1","key":"408_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-11-418","volume":"11","author":"NJ White","year":"2012","unstructured":"White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11(1):418.","journal-title":"Malar J"},{"issue":"4","key":"408_CR25","doi-asserted-by":"publisher","first-page":"e0006230","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12(4):e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"408_CR26","unstructured":"WHO. World Malaria Report 2010. World Health Organization. Geneva, Switzerland. 2010. Accessed on 10 Feb 2021."},{"key":"408_CR27","unstructured":"WHO. World malaria report 2014. World Health Organization. Geneva, Switzerland. 2014. Accessed on 10 Feb 2021."},{"key":"408_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002456","volume":"14","author":"RN Rabinovich","year":"2017","unstructured":"Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. malERA: an updated research agenda for malaria elimination and eradication. PLoS Med. 2017;14:1-17.e1002456.","journal-title":"PLoS Med"},{"key":"408_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40249-016-0151-8","volume":"5","author":"RE Cibulskis","year":"2016","unstructured":"Cibulskis RE, Alonso P, Aponte J, Aregawi M, Barrette A, Bergeron L, et al. Malaria: global progress 2000\u20132015 and future challenges. Infect Dis Poverty. 2016;5:61.","journal-title":"Infect Dis Poverty"},{"key":"408_CR30","unstructured":"WHO. Global Technical Strategy For Malaria 2016\u20132030. World Health Organization Geneva, Switzerland. 2021. Accessed on 05 July 2021."},{"key":"408_CR31","unstructured":"WHO. Universal access to core malaria interventions in high-burden countries. World Health Organization, Geneva, Switzerland. 2018. Accessed on 05 July 2021."},{"key":"408_CR32","unstructured":"WHO. Malaria vector control and personal protection: report of a WHO study group. World Health Organization, Geneva, Switzerland. 2006. Accessed on 05 July 2021."},{"key":"408_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1475-2875-10-80","volume":"10","author":"TL Russell","year":"2011","unstructured":"Russell TL, Govella NJ, Azizi S, Drakeley CJ, Kachur SP, Killeen GF. Increased proportions of outdoor feeding among residual malaria vector populations following increased use of insecticide-treated nets in rural Tanzania. Malar J. 2011;10:80.","journal-title":"Malar J"},{"key":"408_CR34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/1469-0691.12314","volume":"19","author":"C Sokhna","year":"2013","unstructured":"Sokhna C, Ndiath MO, Rogier C. The changes in mosquito vector behaviour and the emerging resistance to insecticides will challenge the decline of malaria. Clin Microbiol Infect. 2013;19:902\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"408_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"A Dondorp","year":"2009","unstructured":"Dondorp A, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455\u201367.","journal-title":"N Engl J Med"},{"issue":"11","key":"408_CR36","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1086\/657120","volume":"51","author":"H Noedl","year":"2010","unstructured":"Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51(11):e82\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"408_CR37","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJMp1108322","volume":"365","author":"AM Dondorp","year":"2011","unstructured":"Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, et al. The threat of artemisinin-resistant malaria. N Engl J Med. 2011;365(12):1073\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"408_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"E Ashley","year":"2014","unstructured":"Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"408_CR39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602\u20138.","journal-title":"Nat Med"},{"issue":"13","key":"408_CR40","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385(13):1163\u201371.","journal-title":"N Engl J Med"},{"issue":"8","key":"408_CR41","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/319689","volume":"183","author":"G Targett","year":"2001","unstructured":"Targett G, Drakeley C, Jawara M, Von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183(8):1254\u20139.","journal-title":"J Infect Dis"},{"key":"408_CR42","unstructured":"WHO. Guidelines for the treatment of malaria. Third edition. World Health Organization. Geneva, Switzerland. 2015. Accessed on 08 July 2021."},{"key":"408_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","volume":"13","author":"NJ White","year":"2013","unstructured":"White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175\u201381.","journal-title":"Lancet Infect Dis"},{"key":"408_CR44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.","journal-title":"Malar J"},{"key":"408_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351.","journal-title":"Malar J"},{"key":"408_CR46","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/424663","volume":"39","author":"JK Baird","year":"2004","unstructured":"Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336\u201345.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"408_CR47","first-page":"397","volume":"59","author":"RS Grewal","year":"1981","unstructured":"Grewal RS. Pharmacology of 8-aminoquinolines. Bull World Health Organ. 1981;59(3):397\u2013406.","journal-title":"Bull World Health Organ"},{"issue":"6","key":"408_CR48","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1586\/17512433.2014.948421","volume":"7","author":"IT Chen","year":"2014","unstructured":"Chen IT, Gosling RD. Targeting Plasmodium falciparum transmission with primaquine: same efficacy, improved safety with a lower dose? Expert Rev Clin Pharmacol. 2014;7(6):681\u20136.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"408_CR49","first-page":"391","volume":"59","author":"DF Clyde","year":"1981","unstructured":"Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ. 1981;59(3):391\u20135.","journal-title":"Bull World Health Organ"},{"issue":"11","key":"408_CR50","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/blood.V84.11.3613.bloodjournal84113613","volume":"84","author":"E Beutler","year":"1994","unstructured":"Beutler E. G6PD deficiency. Blood. 1994;84(11):3613\u201336.","journal-title":"Blood"},{"issue":"4","key":"408_CR51","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4269\/ajtmh.2007.77.779","volume":"77","author":"E Beutler","year":"2007","unstructured":"Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77(4):779\u201389.","journal-title":"Am J Trop Med Hyg"},{"key":"408_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bjh.12665","volume":"1","author":"L Luzzatto","year":"2014","unstructured":"Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;1:469\u201380.","journal-title":"Br J Haematol"},{"issue":"2","key":"408_CR53","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.hoc.2015.11.006","volume":"30","author":"L Luzzatto","year":"2016","unstructured":"Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30(2):373\u201393.","journal-title":"Hematol Oncol Clin North Am"},{"key":"408_CR54","first-page":"621","volume":"22","author":"AS Alving","year":"1960","unstructured":"Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960;22:621\u201331.","journal-title":"Bull World Health Organ"},{"issue":"10","key":"408_CR55","first-page":"1303","volume":"91","author":"L Luzzatto","year":"2006","unstructured":"Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. Hematol J. 2006;91(10):1303\u20136.","journal-title":"Hematol J"},{"key":"408_CR56","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1001\/jama.1952.72930340017010","volume":"149","author":"AS Alving","year":"1952","unstructured":"Alving AS, Arnold J, Robinson DH. Status of primaquine: 1. Mass therapy of subclinical vivax malaria with primaquine. J Am Med Assoc. 1952;149:1558\u201362.","journal-title":"J Am Med Assoc"},{"issue":"17","key":"408_CR57","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jama.1954.02940510011005","volume":"154","author":"CP Archambeault","year":"1954","unstructured":"Archambeault CP. Mass antimalarial therapy in veterans returning from Korea. J Am Med Assoc. 1954;154(17):1411\u20135.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"408_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4269\/ajtmh.1970.19.27","volume":"19","author":"GU Fisher","year":"1970","unstructured":"Fisher GU, Gordon MP, Lobel HO, Runcik K. Malaria in soldiers returning from Vietnam. Epidemiologic, therapeutic, and clinical studies. Am J Trop Med Hyg. 1970;19(1):27\u201339.","journal-title":"Am J Trop Med Hyg"},{"key":"408_CR59","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(00)03127-5","volume":"356","author":"A Kaneko","year":"2000","unstructured":"Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bj\u00f6rkman A. Malaria eradication on islands. Lancet. 2000;356:1560\u20134.","journal-title":"Lancet"},{"key":"408_CR60","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/1475-2875-12-383","volume":"12","author":"MS Hsiang","year":"2013","unstructured":"Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, et al. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013;12:383.","journal-title":"Malar J"},{"key":"408_CR61","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0140-6736(83)90523-8","volume":"322","author":"RM Garfield","year":"1983","unstructured":"Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet. 1983;322:500\u20133.","journal-title":"Lancet"},{"issue":"1","key":"408_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4269\/ajtmh.14-0254","volume":"93","author":"G Newby","year":"2015","unstructured":"Newby G, Hwang J, Koita K, Chen I, Greenwood B, Von SL, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93(1):125\u201334.","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"408_CR63","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.pt.2003.08.003","volume":"19","author":"L Von Seidlein","year":"2003","unstructured":"Von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003;19(10):452\u201360.","journal-title":"Trends Parasitol"},{"issue":"2","key":"408_CR64","first-page":"203","volume":"27","author":"DF Clyde","year":"1962","unstructured":"Clyde DF. Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. Bull World Health Organ. 1962;27(2):203.","journal-title":"Bull World Health Organ"},{"key":"408_CR65","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1136\/bmj.1.5236.1346","volume":"1346","author":"AC Allison","year":"1961","unstructured":"Allison AC, Clyde D. Malaria in African children with deficient erythrocyte glucose-6-phosphate dehydrogenase. Br Med J. 1961;1346:1346\u20139.","journal-title":"Br Med J"},{"key":"408_CR66","unstructured":"Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. World Health Organization. Geneva, Switzerland. 2014. Accessed on 10 July 2021."},{"key":"408_CR67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S0035-9203(96)90099-1","volume":"90","author":"D Luo","year":"1996","unstructured":"Luo D, Shang L, Liu X, You X. A successful control programme for falciparum malaria in Xinyang, China. Trans R Soc Trop Med Hyg. 1996;90:100\u20132.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"408_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3347\/kjp.2006.44.4.285","volume":"44","author":"ET Han","year":"2006","unstructured":"Han ET, Lee DH, Park KD, Seok WS, Kim YS, Tsuboi T, et al. Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol. 2006;44(4):285\u201394.","journal-title":"Korean J Parasitol"},{"key":"408_CR69","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3346\/jkms.2005.20.5.707","volume":"20","author":"JS Yeom","year":"2005","unstructured":"Yeom JS, Ryu SH, Oh S, Choi DH, Song KJ, Oh YH, et al. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci. 2005;20:707\u201312.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"408_CR70","first-page":"75","volume":"3","author":"SD Pant","year":"2014","unstructured":"Pant SD, Chol KY, Tegegn Y, Mandal PP, Chol RK. Mass primaquine preventive treatment for control of Plasmodium vivax malaria in the Democratic People\u2019s Republic of Korea: a country success story. Policy Pract. 2014;3(1):75\u201380.","journal-title":"Policy Pract"},{"issue":"11","key":"408_CR71","first-page":"1670","volume":"67","author":"C Deng","year":"2018","unstructured":"Deng C, Huang B, Wang Q, Wu W, Zheng S, Zhang H, et al. Large-scale artemisinin\u2013piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clin Infect Dis. 2018;67(11):1670\u20136.","journal-title":"Clin Infect Dis"},{"key":"408_CR72","unstructured":"WHO. Guidelines for the treatment of malaria. Second edition. World Health Organization. Geneva, Switzerland. 2010. Accessed on 10 July 2021."},{"key":"408_CR73","unstructured":"WHO. WHO Evidence Review Group: The Safety and Effectiveness of Single Dose Primaquine as a P. falciparum gametocytocide. World Health Organization, Geneva, Switzerland. 2012. Accessed on 10 July 2021."},{"key":"408_CR74","unstructured":"WHO. Updated WHO policy recommendation: Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. World Health Organization. Geneva, Switzerland. 2012. Accessed on 10 July 2021."},{"key":"408_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-016-0581-y","volume":"14","author":"BP Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves BP, Tiono AB, Ou\u00e9draogo A, Guelb\u00e9ogo WM, Bradley J, Nebie I, et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med. 2016;14:1.","journal-title":"BMC Med"},{"key":"408_CR76","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","volume":"18","author":"A Dicko","year":"2018","unstructured":"Dicko A, Roh ME, Diawara H, Mahamar A, Soumare HM, Lanke K, et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Lancet Infect Dis. 2018;18:627\u201339.","journal-title":"Lancet Infect Dis"},{"key":"408_CR77","first-page":"498","volume":"2020","author":"K Stepniewska","year":"2020","unstructured":"Stepniewska K, Humphreys GS, Gon\u00e7alves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J Infect Dis. 2020;2020:498.","journal-title":"J Infect Dis"},{"key":"408_CR78","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.02108-19","volume":"64","author":"A Vantaux","year":"2020","unstructured":"Vantaux A, Kim S, Piv E, Chy S, Berne L, Khim N, et al. Significant efficacy of a single low dose of primaquine compared to stand-alone artemisinin combination therapy in reducing gametocyte carriage in cambodian patients with uncomplicated multidrug-resistant Plasmodium falciparum Malaria. Antimicrob Agents Chemother. 2020;64:6.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"408_CR79","doi-asserted-by":"publisher","first-page":"e0151898","DOI":"10.1371\/journal.pone.0151898","volume":"11","author":"G Bancone","year":"2016","unstructured":"Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, et al. Single low dose primaquine (0.25mg\/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS ONE. 2016;11(3):e0151898.","journal-title":"PLoS ONE"},{"key":"408_CR80","unstructured":"NMCP. National Guidelines for malaria diagnosis, treatment and preventive therapies 2020. National Malaria Control Programme, Dodoma, Tanzania. 2020. Accessed on July 20, 2021."},{"key":"408_CR81","doi-asserted-by":"publisher","first-page":"19060","DOI":"10.1038\/s41598-019-55437-8","volume":"9","author":"W Kagaya","year":"2019","unstructured":"Kagaya W, Gitaka J, Chan CW, Kongere J, Idris Z, Deng C, et al. Malaria resurgence after significant reduction by mass drug administration on Ngodhe Island, Kenya. Sci Rep. 2019;9:19060.","journal-title":"Sci Rep"},{"key":"408_CR82","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12916-018-1202-8","volume":"16","author":"U Morris","year":"2018","unstructured":"Morris U, Msellem MI, Mkali H, Islam A, Aydin-schmidt B, Jovel I, et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting\u2014high coverage and safety, but no significant impact on transmission. BMC Med. 2018;16:215.","journal-title":"BMC Med"},{"issue":"11","key":"408_CR83","doi-asserted-by":"publisher","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri O, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339.","journal-title":"PLoS Med"},{"key":"408_CR84","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/cid\/ciy235","volume":"67","author":"ME Gilder","year":"2018","unstructured":"Gilder ME, Hanpithakphong W, Hoglund RM, Tarning J, Win HH, Hilda N, et al. Primaquine pharmacokinetics in lactating women and breastfed infant exposures. Clin Infect Dis. 2018;67:1000\u20137.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"408_CR85","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1159\/000327673","volume":"20","author":"C Igbeneghu","year":"2011","unstructured":"Igbeneghu C, Odaibo AB, Olaleye DO. Impact of asymptomatic malaria on some hematological parameters in the iwo community in southwestern Nigeria. Med Princ Pract. 2011;20(5):459\u201363.","journal-title":"Med Princ Pract"},{"key":"408_CR86","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1586\/eri.13.45","volume":"11","author":"KA Lindblade","year":"2013","unstructured":"Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Lindblade KA, Steinhardt L, et al. The silent threat: asymptomatic parasitemia and malaria transmission. Expert Rev Anti Infect Ther. 2013;11:6.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"408_CR87","doi-asserted-by":"publisher","first-page":"e1001942","DOI":"10.1371\/journal.pmed.1001942","volume":"13","author":"I Chen","year":"2016","unstructured":"Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, et al. \u201cAsymptomatic\u201d malaria: a chronic and debilitating infection that should be treated. PLoS Med. 2016;13:e1001942.","journal-title":"PLoS Med"},{"issue":"2","key":"408_CR88","first-page":"321","volume":"11","author":"H Gholmreza","year":"2017","unstructured":"Gholmreza H, Mehdi M, Hojjat Z, Ahmad R, Hossein K. Asymptomatic malaria and its challenges in the malaria elimination program in Iran: a systematic review. J Arthropod Borne Dis. 2017;11(2):321\u201330.","journal-title":"J Arthropod Borne Dis"},{"issue":"2","key":"408_CR89","doi-asserted-by":"publisher","first-page":"e1000407","DOI":"10.1371\/journal.pmed.1000407","volume":"8","author":"A Dicko","year":"2011","unstructured":"Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in. PLoS Med. 2011;8(2):e1000407.","journal-title":"PLoS Med"},{"issue":"9","key":"408_CR90","doi-asserted-by":"publisher","first-page":"e0162718","DOI":"10.1371\/journal.pone.0162718","volume":"11","author":"H Maiga","year":"2016","unstructured":"Maiga H, Lasry E, Diarra M, Sagara I, Bamadio A, Traore A, et al. Seasonal malaria chemoprevention with sulphadoxine-pyrimethamine and amodiaquine selects pfdhfr-dhps quintuple mutant genotype in Mali. PLoS ONE. 2016;11(9):e0162718.","journal-title":"PLoS ONE"},{"key":"408_CR91","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12936-017-1974-x","volume":"16","author":"F Diawara","year":"2017","unstructured":"Diawara F, Steinhardt LC, Mahamar A, Traore T, Kone DT, Diawara H, et al. Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali. Malar J. 2017;16:325.","journal-title":"Malar J"},{"key":"408_CR92","doi-asserted-by":"publisher","first-page":"81082","DOI":"10.1038\/s41598-018-26474-6","volume":"8","author":"T Druetz","year":"2018","unstructured":"Druetz T. Evaluation of direct and indirect effects of seasonal malaria chemoprevention in Mali. Sci Rep. 2018;8:81082.","journal-title":"Sci Rep"},{"key":"408_CR93","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ncomms1879","volume":"3","author":"M Cairns","year":"2012","unstructured":"Cairns M, Roca-feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, et al. Estimating the potential of public health impact of seasonal malaria chemoprevention in African children. Nat Commun. 2012;3:881.","journal-title":"Nat Commun"}],"container-title":["Tropical Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-022-00408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41182-022-00408-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-022-00408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T18:10:01Z","timestamp":1666375801000},"score":1,"resource":{"primary":{"URL":"https:\/\/tropmedhealth.biomedcentral.com\/articles\/10.1186\/s41182-022-00408-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1186\/s41182-022-00408-5","relation":{},"ISSN":["1349-4147"],"issn-type":[{"value":"1349-4147","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and approval to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they do not have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}